TG Therapeutics, Inc. $TGTX Stock Acquired by Profund Advisors LLC

Profund Advisors LLC grew its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 26.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 46,230 shares of the biopharmaceutical company’s stock after acquiring an additional 9,717 shares during the quarter. Profund Advisors LLC’s holdings in TG Therapeutics were worth $2,579,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in TGTX. BlackRock Inc. bought a new position in TG Therapeutics during the second quarter valued at about $1,211,429,000. Bank of America Corp DE purchased a new position in TG Therapeutics in the second quarter valued at about $71,960,000. Bank of New York Mellon Corp bought a new position in shares of TG Therapeutics during the 2nd quarter valued at approximately $49,472,000. Dimensional Fund Advisors LP increased its stake in shares of TG Therapeutics by 129.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,084,855 shares of the biopharmaceutical company’s stock worth $36,029,000 after purchasing an additional 612,068 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of TG Therapeutics by 697.6% during the 2nd quarter. Wellington Management Group LLP now owns 478,265 shares of the biopharmaceutical company’s stock worth $26,276,000 after purchasing an additional 418,300 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Laurence Charney sold 5,000 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $54.96, for a total transaction of $274,800.00. Following the sale, the director owned 168,640 shares of the company’s stock, valued at approximately $9,268,454.40. This represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 8.87% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. B. Riley Financial upped their price objective on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research note on Monday, July 27th. JPMorgan Chase & Co. raised their target price on TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings lowered TG Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. HC Wainwright reaffirmed a “buy” rating and set a $78.00 price target on shares of TG Therapeutics in a research report on Tuesday, September 1st. Finally, Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 6th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $63.00.

TG Therapeutics Price Performance

TGTX opened at $61.18 on Monday. The company has a 50 day moving average of $55.33 and a 200 day moving average of $43.75. The company has a market cap of $9.36 billion, a PE ratio of 22.33, a price-to-earnings-growth ratio of 2.58 and a beta of 1.80. TG Therapeutics, Inc. has a 12 month low of $26.76 and a 12 month high of $61.76. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). The business had revenue of $240.34 million for the quarter, compared to the consensus estimate of $229.77 million. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The company’s revenue was up 70.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.17 EPS. On average, sell-side analysts expect that TG Therapeutics, Inc. will post 0.92 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for B-cell diseases, including multiple sclerosis and certain blood cancers. The company’s research and development programs are centered on therapies that target B cells and the immune system.

TG Therapeutics’ primary marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of relapsing forms of multiple sclerosis in adults.